Skip to Main Content

Xiaojia (Sasha) Guo, PhD

Research Scientist (Nephrology)
DownloadHi-Res Photo

About

Titles

Research Scientist (Nephrology)

Appointments

Other Departments & Organizations

Education & Training

Postdoctoral fellow
Weill Medical College of Cornell Univ (2000)
PhD
Rutgers University, Cell and Developmental Biology (1994)
MSc
University of Western Ontario, Biochemistry (1990)
BA
Jiangxi University, Microbilogy (1982)

Research

Overview

We have shown that ESDN down-regulation by RNA interference significantly enhanced PDGF-induced VSMC DNA synthesis and migration. This was associated with increased ERK1/2, Src, and PDGF receptor (PDGFR) phosphorylation, without altering total PDGFR expression levels. In binding assays, ESDN down-regulation significantly increased 125I-PDGF maximum binding (Bmax) to PDGF receptors on VSMCs without altering the binding constant (Kd), raising the possibility that ESDN regulates PDGFR processing. ESDN down-regulation significantly reduced ligand-induced PDGFR ubiquitination. This was associated with a significant reduction in the expression level of c-Cbl, an E3 ubiquitin ligase that ubiquitinylates PDGFR. Thus, ESDN modulates PDGF signaling in VSMCs via regulation ofPDGFRsurface levels. The ESDN effect is mediated, at least in part, through effects on PDGFR ubiquitination.

Continued detailed analyses of the involvement of ESDN in the regulation of RTK-driven pathologies is thus predicted to pave the way for therapeutic strategy for vascular diseases and other diseases involving RTK-driven tissue remodeling.

Medical Subject Headings (MeSH)

Nephrology; Vascular Remodeling

Research at a Glance

Yale Co-Authors

Frequent collaborators of Xiaojia (Sasha) Guo's published research.

Publications

2024

2023

2022

Academic Achievements & Community Involvement

  • activity

    West Haven VA Medical Center

  • activity

    Utility of Renalase as a Novel Biomarker to Stratify Pancreatic Adenocarcinoma Candidates for Surgery

  • activity

    Heightened Innate Immune Response to COVID-19 Infection in CKD: Implications to Poorer Outcome During CKD.

  • activity

    mRNA editing via Apobec-1 limits regulated necrosis from cisplatin (CP)-induced Acute Kidney Injury (AKI) by regulating the disposal of pro-ferroptotic triglycerides

  • activity

    A Renalase Peptide Encapsulated in Renal-selective Mesoscale Nanoparticle Protected Cisplatin-induced Chronic Kidney Disease

Get In Touch

Contacts

Locations